Evaluation of p63 and p504s markers for the diagnosis of prostate cancer;Évaluation des marqueurs p63 et p504s dans le diagnostic du cancer de prostate

Annales de Pathologie

Volumn 28, Issue 5, 2008, Pages 417-423

  Molinié, Vincent ^a   Vieillefond, Annick ^b   Michiels, Jean François ^c  

^a SAINT JOSEPH HOSPITAL   (France)

^b Institut Cochin   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Immunohistochemistry; p504s; p63; Prostate cancer; Racemase

Indexed keywords

ANTIBODY; ONCOPROTEIN; PROTEIN P504S; PROTEIN P63; TUMOR MARKER; UNCLASSIFIED DRUG; 2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; CKAP4 PROTEIN, HUMAN; ISOMERASE; MEMBRANE PROTEIN;

ARTICLE; EVALUATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PROSTATE BIOPSY; PROSTATE CANCER; BIOPSY; CELL NUCLEUS; CYTOPLASM; ENZYMOLOGY; GENETIC MARKER; GENETICS; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

BIOPSY; CELL NUCLEUS; CYTOPLASM; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES;

EID: 55049128074     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2008.05.004     Document Type: Article

References (20)

1. Fournier G., Valeri A., Mangin P., and Cussenot O. Cancer de prostate. Épidémiologie. Facteurs de risque. Ann Urol (Paris) 38 5 (2004) 187-206
2. Bauvin E., Remontet L., and Grosclaude P. Incidence et mortalité due au cancer de prostate en France : évolution entre 1978 et 1990. Prog Urol 13 6 (2003) 1334-1339
3. Soulié M., Rebillard X., and Villers A. Dépistage du cancer de prostate. Prog Urol 13 5 Suppl. 2 (2003) 1272-1275
4. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 9361 (2003) 955-964
5. Parsons J.K., and Partin A.W. Clinical interpretation of prostate biopsy reports. Urology 67 3 (2006) 452-457
6. Iczkowski K.A. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med 130 6 (2006) 835-843
7. Molinié V. Modifications histologiques de la prostate normale et pathologique après traitement hormonal et radiothérapie. Impact sur l'interprétation sur le score de Gleason. Prog Urol 16 1 Suppl. (2006) 10-15
8. Molinié V. Foyer minime, foyer suspect et néoplasies intra-épithéliales prostatiques de haut grade. Quelles significations ? Quelles conséquences ?. Prog Urol 14 1 Suppl. (2004) 2-6
9. Hameed O., and Humphrey P.A. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 22 1 (2005) 88-104
10. Molinié V., Fromont G., Sibony M., Vieillefond A., Vassiliu V., Cochand-Priollet B., et al. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol 17 10 (2004) 1180-1190
11. Molinié V., Hervé J.M., Lugagne P.M., Lebret T., and Botto H. Diagnostic utility of a p63/alpha-methyl coenzyme A racemase (p504s) cocktail in ambiguous lesions of the prostate upon needle biopsy. BJU Int 97 5 (2006) 1109-1115
12. Molinié V., Hervé J.M., Lugagne P.M., Yonneau L., Ellard S., Lebret T., et al. Value of new prostate cancer markers: alpha methylacyl CoA racemase (p504S) and p63. Prog Urol 15 4 (2005) 611-615
13. Stewart J.M., Fleshner N., Cole H., and Sweet J. Comparison of Annexin II, p63 and AMACR immunoreactivity in prostatic tissue: A tissue micro-array study. J Clin Pathol (2006)
14. Vanguri V.K., Woda B.A., and Jiang Z. Sensitivity of p504s/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies. Appl Immunohistochem Mol Morphol 14 3 (2006) 365-368
15. Molinié V., Balaton A., Rotman S., Mansouri D., De Pinieux I., Homsi T., et al. Alpha-methyl CoA racemase expression in renal cell carcinomas. Hum Pathol 37 6 (2006) 698-703
16. Went P.T., Sauter G., Oberholzer M., and Bubendorf L. Abundant expression of AMACR in many distinct tumour types. Pathology 38 5 (2006) 426-432
17. Hameed O., and Humphrey P.A. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol 124 5 (2005) 708-715
18. Varma M., and Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 47 1 (2005) 1-16
19. Penault-Llorca F., Balaton A., Sabourin J.C., and Le Doussal V. Évaluation du statut d'HER2 dans le cancer du sein infiltrant : protocole technique et recommandations d'interprétation. Ann Pathol 22 2 (2002) 150-157
20. Kunju L.P., Chinnaiyan A.M., and Shah R.B. Comparison of monoclonal antibody (p504s) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology 47 6 (2005) 587-596